Management of recurrent urinary tract infection in an older female

Definition, and the essential first step. Recurrent UTI is two culture-proven episodes in 6 months, or three in 12 months. The first management step is to confirm that each episode really was a symptomatic, culture-proven infection. The commonest reason an older woman carries a label of "recurrent UTI" is repeated treatment of asymptomatic bacteriuria — which Kane's is explicit about: bacteriuria in older persons is common and usually asymptomatic, and in the absence of obstructive uropathy there is no evidence to support routine antimicrobial therapy. Review the actual culture and symptom records before doing anything else.

Look for and correct the reversible cause. Genitourinary syndrome of menopause — vaginal and urethral atrophy; incomplete bladder emptying — measure the post-void residual; pelvic organ prolapse and cystocele; constipation and faecal incontinence; inadequate fluid intake; diabetes with glycosuria; stones or obstruction; catheter use; and immobility or cognitive impairment causing difficulty in toileting. Examine the perineum, perform a pelvic examination, and assess the functional and cognitive ability to reach and use the toilet — this last is a genuinely geriatric point that is often the actual cause.

Investigations. Urine culture with sensitivity for each episode — both to direct therapy and to track resistance; blood glucose and HbA1c; renal function; post-void residual by bladder scan; and ultrasound of kidneys, ureters and bladder. Referral for cystoscopy and further imaging is indicated only if there is haematuria, a suspected stone or obstruction, a suspected fistula, persistent infection with the same organism, or failure of conservative management — routine cystoscopy in every older woman is not indicated.

Behavioural and fluid measures — first line. Increase fluid intake to about 1.5–2 L per day if current intake is below 1.5 L (proven in a randomised trial); timed, complete and double voiding; treat constipation; perineal hygiene; avoid spermicides; and avoid unnecessary catheterisation. If there is a significant post-void residual, manage it with bladder retraining or clean intermittent catheterisation rather than an indwelling catheter.

Vaginal oestrogen — the single most important intervention in a postmenopausal woman. Low-dose vaginal oestrogen cream, pessary or ring restores the vaginal epithelium, lowers vaginal pH and re-establishes lactobacilli, significantly reducing recurrence. Systemic absorption is negligible, so age is not a barrier, and it can generally be used in women with a history of breast cancer after discussion with the oncologist. Systemic hormone replacement therapy does NOT work for this indication — a favourite examiner distinction.

Antiseptic and antibiotic prophylaxis — only after the above. Methenamine hippurate 1 g twice daily is a urinary antiseptic that is not an antibiotic and was shown non-inferior to daily antibiotic prophylaxis in the ALTAR randomised trial — it is now the preferred first prophylactic step. Cranberry products and D-mannose may be offered (weak evidence). If antibiotic prophylaxis is still required: low-dose continuous prophylaxis for 3–6 months — nitrofurantoin 50–100 mg nightly (avoid if eGFR <45, avoid prolonged use because of pulmonary fibrosis and hepatotoxicity, and note it is on the Beers list in renal impairment), trimethoprim 100 mg nightly, or cefalexin 125–250 mg nightly — or post-coital prophylaxis where episodes relate to intercourse. Self-start standby therapy with a culture-directed agent is useful in a reliable, cognitively intact woman. Never perform a test-of-cure culture in an asymptomatic patient.

The AUA/CUA/SUFU 2025 amendment to the recurrent uncomplicated UTI guideline substantially expanded the non-antibiotic options: clinicians may now offer cranberry, methenamine hippurate, and increased water intake (where intake is below 1.5 L/day) for prophylaxis; vaginal oestrogen remains a "should recommend" for peri- and postmenopausal women; and a new recommendation directs clinicians to evaluate for an alternative cause of symptoms in women whose symptoms persist after microbiological cure. NICE (2024) similarly now recommends methenamine hippurate as an alternative to daily antibiotic prophylaxis where behavioural measures and vaginal oestrogen have not been sufficient. This shift is a direct antimicrobial stewardship gain in a population that accounts for a disproportionate share of community antibiotic prescribing.